Replimune Group, Inc. announced on November 25, 2024, the pricing of an upsized public offering of its common stock and pre-funded warrants. The offering included 6,923,000 shares of common stock at $13.00 per share and pre-funded warrants to purchase 3,846,184 shares at a purchase price of $12.9999 per warrant.
The aggregate gross proceeds from the offering are expected to be approximately $140 million before deducting underwriting discounts and commissions. Replimune also granted the underwriter a 30-day option to purchase up to an additional 1,615,377 shares of common stock, which was exercised in full on November 26, 2024.
The company estimates that the net proceeds from the offering will be approximately $155.8 million, after accounting for underwriting discounts, commissions, and estimated offering expenses. This capital raise is expected to strengthen Replimune's financial position, supporting its ongoing clinical development and commercialization preparations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.